Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of the liver targeted stearoyl-coenzyme A desaturase-1, modulator Aramchol, an oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH) for variable populations, as well as other liver associated disorders. Co.'s product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule that Co. is developing for oral treatment for NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The GLMD stock yearly return is shown above.
The yearly return on the GLMD stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the GLMD annual return calculation with any dividends reinvested as applicable (on ex-dates).
|